Evidence map›Paper›PMID 35222927›Full record

ArticleChemical science2022

Fighting metallodrug resistance through alteration of drug metabolism and blockage of autophagic flux by mitochondria-targeting AIEgens.

Yan Su, Hai Lin, Ying Tu, Meng-Meng Wang, Guan-Dong Zhang, Jin Yang, Hong-Ke Liu, Zhi Su

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yan SuJiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University Nanjing 210023 China zhisu@njnu.edu.cn liuhongke@njnu.edu.cn.ORCID https://orcid.org/0000-0002-9974-1161
Hai LinJiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University Nanjing 210023 China zhisu@njnu.edu.cn liuhongke@njnu.edu.cn.
Ying TuJiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University Nanjing 210023 China zhisu@njnu.edu.cn liuhongke@njnu.edu.cn.
Meng-Meng WangJiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University Nanjing 210023 China zhisu@njnu.edu.cn liuhongke@njnu.edu.cn.
Guan-Dong ZhangJiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University Nanjing 210023 China zhisu@njnu.edu.cn liuhongke@njnu.edu.cn.
Jin YangJiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University Nanjing 210023 China zhisu@njnu.edu.cn liuhongke@njnu.edu.cn.
Hong-Ke LiuJiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University Nanjing 210023 China zhisu@njnu.edu.cn liuhongke@njnu.edu.cn.ORCID https://orcid.org/0000-0002-0968-6518
Zhi SuJiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University Nanjing 210023 China zhisu@njnu.edu.cn liuhongke@njnu.edu.cn.ORCID https://orcid.org/0000-0003-1690-527X
Nanjing Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metallodrug resistance has attracted a great deal of attention in cancer treatment. According to the cisplatin (cis-Pt) anticancer mechanism, a new strategy to overcome cis-Pt resistance through mitochondrial dysfunction is proposed. Two mitochondria-targeted aggregation-induced emission fluorogens (AIEgens) were first synthesized, named DP-PPh

Identifiers

PMID35222927
PMCPMC8809423
OpenAlexW4205517753

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.